1/29
09:24 am
pbm
Court sides with psychedelic biotech, over hedge fund [Advisor.ca (Canada)]
Low
Report
Court sides with psychedelic biotech, over hedge fund [Advisor.ca (Canada)]
1/29
09:22 am
pbm
Court sides with psychedelic biotech, over hedge fund [Investment Executive - News]
Medium
Report
Court sides with psychedelic biotech, over hedge fund [Investment Executive - News]
1/28
06:30 pm
pbm
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Low
Report
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
1/22
01:42 pm
pbm
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Low
Report
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
1/20
07:19 am
pbm
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
Neutral
Report
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
1/14
07:00 pm
pbm
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Low
Report
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
1/12
08:30 am
pbm
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
Medium
Report
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
1/5
11:28 am
pbm
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash [Canadian Business Journal (Canada)]
Medium
Report
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash [Canadian Business Journal (Canada)]
1/5
09:15 am
pbm
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
Medium
Report
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
12/19
07:49 am
pbm
Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial [Yahoo! Finance]
High
Report
Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial [Yahoo! Finance]
12/19
07:28 am
pbm
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial [Canadian Business Journal (Canada)]
High
Report
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial [Canadian Business Journal (Canada)]
12/19
07:00 am
pbm
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
High
Report
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
12/9
07:00 am
pbm
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
Medium
Report
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
11/25
07:28 am
pbm
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program [Canadian Business Journal (Canada)]
Medium
Report
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program [Canadian Business Journal (Canada)]
11/25
07:00 am
pbm
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
Low
Report
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
11/20
07:50 am
pbm
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets [Yahoo! Finance]
High
Report
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets [Yahoo! Finance]
11/20
07:00 am
pbm
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
High
Report
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
11/12
07:00 am
pbm
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
Medium
Report
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs